Heron Therapeutics, Inc.
HRTX
$0.84
-$0.03-3.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.47% | 16.47% | 3.26% | 12.21% | 19.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.47% | 16.47% | 3.26% | 12.21% | 19.13% |
| Cost of Revenue | 344.12% | 10.49% | -14.44% | -17.74% | -110.38% |
| Gross Profit | -12.04% | 20.87% | 15.83% | 30.29% | 105.40% |
| SG&A Expenses | 10.70% | 15.32% | -5.35% | -5.31% | 76.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.77% | 13.52% | -8.55% | -9.42% | 36.33% |
| Operating Income | -99.09% | 8.19% | 74.60% | 165.74% | -43.46% |
| Income Before Tax | -180.64% | -260.87% | 74.22% | 183.39% | 134.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -180.64% | -260.87% | 74.22% | 183.39% | 134.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -180.64% | -260.87% | 74.22% | 183.39% | 134.16% |
| EBIT | -99.09% | 8.19% | 74.60% | 165.74% | -43.46% |
| EBITDA | -87.90% | 10.29% | 82.32% | 190.17% | -41.27% |
| EPS Basic | -165.69% | -223.97% | 74.42% | 182.30% | 134.14% |
| Normalized Basic EPS | -137.00% | -14.14% | 74.41% | 181.68% | -25.82% |
| EPS Diluted | -165.69% | -223.97% | 67.00% | 147.85% | 134.14% |
| Normalized Diluted EPS | -137.00% | -14.14% | 74.41% | 164.12% | -25.82% |
| Average Basic Shares Outstanding | 22.77% | 11.46% | 1.13% | 1.52% | -0.03% |
| Average Diluted Shares Outstanding | 22.77% | 11.46% | 1.13% | 30.24% | -0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |